KamyarAfsharDO

Cystic Fibrosis, Interstitial Lung Diseases, Lung Transplantation Medicine, Restrictive Lung Disease

Clinical Professor of Medicine Medical Director, UC San Diego Lung Transplant Program

Dr. Afshar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
9300 Campus Point Drive
La Jolla, CA 92037
Phone+1 858-657-5050

Fax+1 858-657-7636

Kamyar Afshar, DO, is a pulmonologist based in San Diego, CA, with subspecialties in cystic fibrosis, interstitial lung diseases, lung transplantation medicine, and restrictive lung disease. He completed his residency in internal medicine and fellowship in pulmonary disease and critical care medicine at the University of Southern California/Los Angeles General Medical Center, graduating from the Arizona College of Osteopathic Medicine in 2002. He currently practices at UC San Diego Health as a pulmonary and critical care medicine physician. His expertise includes alpha-1 anti-trypsin deficiency, lung transplantation, and critical care medicine. Dr. Afshar has published several research articles, including studies on lung transplantation in COVID-19 patients and idiopathic pulmonary fibrosis.

University of Southern California/Los Angeles General Medical Center (USC/LA General)Fellowship, Pulmonary Disease and Critical Care Medicine, 2005 - 2008
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 2002 - 2005
Arizona College of Osteopathic Medicine of Midwestern UniversityClass of 2002

PubMed

Lung Transplant Success in COVID-19 Patients Requiring V-V ECMO: One-Year Follow-Up.
Mazen F Odish, Travis Pollema, Christine M Lin, Robert L Owens, Cassia Yi
Annals of Transplantation. 2024-12-24
Integrated multiomic analysis identifies TRIP13 as a mediator of alveolar epithelial type II cell dysfunction in idiopathic pulmonary fibrosis.
Laurence St Pierre, Asres Berhan, Eun K Sung, Juan R Alvarez, Hongjun Wang
Biochimica Et Biophysica Acta. Molecular Basis of Disease. 2024-11-13
2 citations
Context-dependent roles of mitochondrial LONP1 in orchestrating the balance between airway progenitor versus progeny cells.
Le Xu, Chunting Tan, Justinn Barr, Nicole Talaba, Jamie Verheyden
Cell Stem Cell. 2024-10-03

COVID Y Los Pulmones: Los Trasplantes Son El Último Recurso Para Muchos Pacientes De CaliforniaOctober 14th, 2021
COVID Lungs: Transplants Are Last Resort for Many California PatientsOctober 13th, 2021
UC San Diego Health Performed Region’s First Double Lung Transplant for a COVID-19 PatientAugust 24th, 2021
Join now to see all